Literature DB >> 6322790

Effect of bepridil on the activity of cytochrome c oxidase in solution and in proteoliposomes.

E Antonini, M Brunori, A Colosimo, P Sarti.   

Abstract

The interaction between bepridil and mitochondrial cytochrome c oxidase has been studied using the purified enzyme either in aqueous suspensions in the presence of detergents, or embedded into phospholipid vesicles. The investigation, systematically extended to nonactin and valinomycin for comparison, showed that: (a) valinomycin and nonactin induce similar changes in the visible absorption spectrum of cytochrome oxidase; these changes are quite different from those induced by bepridil. (b) The three compounds have an effect on the functional properties of purified, solubilized oxidase which may be related to binding. In particular, bepridil displays a complex pH-dependent effect which at concentrations below 50 microM results in a stimulation of the activity of approximately 30% starting with the oxidized resting enzyme. At variance with valinomycin and nonactin, the stimulatory effect is the same, within the errors, for the detergent-suspended, the vesicle-embedded and even the Keilin-Hartree particles. (c) In the case of detergent-suspended oxidase, the stimulatory effect of bepridil is also similar whether the enzyme is in the resting or in the pulsed state. If the oxidase is embedded into vesicles, however, the pulsed state is significantly more sensitive to bepridil than the resting one. These results are discussed in the light of the possible role assigned to pulsed oxidase in the regulation of the electron flux through the respiratory chain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322790     DOI: 10.1016/0006-2952(84)90377-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  1 in total

1.  Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man.

Authors:  C Funck-Brentano; P L Chaffin; G R Wilkinson; B McAllister; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.